Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Scagliotti, GV, Gaafar, R, Nowak, AK, Nakano, T, van Meerbeeck, J, Popat, S, Vogelzang, NJ, Grosso, F, Aboelhassan, R, Jakopovic, M, Ceresoli, GL, Taylor, P, Orlandi, F, Fennell, DA, Novello, S, Scherpereel, A, Kuribayashi, K, Cedres, S, Sørensen, JB, Pavlakis, N, Reck, M, Velema, D, von Wangenheim, U, Kim, M, Barrueco, J & Tsao, AS 2019, 'Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial' The Lancet Respiratory Medicine, vol. 7, no. 7, pp. 569-580. https://doi.org/10.1016/S2213-2600(19)30139-0

APA

CBE

Scagliotti GV, Gaafar R, Nowak AK, Nakano T, van Meerbeeck J, Popat S, Vogelzang NJ, Grosso F, Aboelhassan R, Jakopovic M, Ceresoli GL, Taylor P, Orlandi F, Fennell DA, Novello S, Scherpereel A, Kuribayashi K, Cedres S, Sørensen JB, Pavlakis N, Reck M, Velema D, von Wangenheim U, Kim M, Barrueco J, Tsao AS. 2019. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. The Lancet Respiratory Medicine. 7(7):569-580. https://doi.org/10.1016/S2213-2600(19)30139-0

MLA

Vancouver

Author

Scagliotti, Giorgio V ; Gaafar, Rabab ; Nowak, Anna K ; Nakano, Takashi ; van Meerbeeck, Jan ; Popat, Sanjay ; Vogelzang, Nicholas J ; Grosso, Federica ; Aboelhassan, Rasha ; Jakopovic, Marko ; Ceresoli, Giovanni L ; Taylor, Paul ; Orlandi, Francisco ; Fennell, Dean A ; Novello, Silvia ; Scherpereel, Arnaud ; Kuribayashi, Kozo ; Cedres, Susana ; Sørensen, Jens Benn ; Pavlakis, Nick ; Reck, Martin ; Velema, Derek ; von Wangenheim, Ute ; Kim, Miyoung ; Barrueco, José ; Tsao, Anne S. / Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso) : a double-blind, randomised, placebo-controlled phase 3 trial. In: The Lancet Respiratory Medicine. 2019 ; Vol. 7, No. 7. pp. 569-580.

Bibtex

@article{4e415b2e3b8c46feb43c4d5d34cc1300,
title = "Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial",
abstract = "BACKGROUND: Nintedanib targets VEGF receptors 1-3, PDGF receptors α and β, FGF receptors 1-3, and Src and Abl kinases, which are all implicated in malignant pleural mesothelioma pathogenesis. Here, we report the final results of the phase 3 part of the LUME-Meso trial, which aimed to investigate the efficacy and safety of pemetrexed plus cisplatin combined with nintedanib or placebo in unresectable malignant pleural mesothelioma.METHODS: This double-blind, randomised, placebo-controlled phase 3 trial was done at 120 academic medical centres and community clinics in 27 countries across the world. Chemotherapy-naive adults (aged ≥18 years) with unresectable epithelioid malignant pleural mesothelioma and ECOG performance status 0-1 were randomly assigned 1:1 via an independently verified random number-generating system to receive up to six 21-day cycles of pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on day 1, then nintedanib (200 mg twice daily) or matched placebo on days 2-21. Patients without disease progression after six cycles received nintedanib or placebo maintenance on days 1-21 of each cycle. The primary endpoint was progression-free survival (investigator-assessed according to mRECIST) in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of their assigned study drug. This study is registered with ClinicalTrials.gov, number NCT01907100.FINDINGS: Between April 14, 2016, and Jan 5, 2018, 541 patients were screened and 458 were randomly assigned to either the nintedanib group (n=229) or the placebo group (n=229). Median treatment duration was 5·3 months (IQR 2·8-7·3) in the nintedanib group and 5·1 months (2·7-7·8) in the placebo group. After 250 events, progression-free survival was not different between the nintedanib group (median 6·8 months [95{\%} CI 6·1-7·0]) and the placebo group (7·0 months [6·7-7·2]; HR 1·01 [95{\%} CI 0·79-1·30], p=0·91). The most frequently reported grade 3 or worse adverse event in both treatment groups was neutropenia (73 [32{\%}] in the nintedanib group vs 54 [24{\%}] in the placebo group). Serious adverse events were reported in 99 (44{\%}) patients in the nintedanib group and 89 (39{\%}) patients in the placebo group. The only serious adverse event occurring in at least 5{\%} of patients in either group was pulmonary embolism (13 [6{\%}] vs seven [3{\%}]).INTERPRETATION: The primary progression-free survival endpoint of the phase 3 part of LUME-Meso was not met and phase 2 findings were not confirmed. No unexpected safety findings were reported.FUNDING: Boehringer Ingelheim.",
author = "Scagliotti, {Giorgio V} and Rabab Gaafar and Nowak, {Anna K} and Takashi Nakano and {van Meerbeeck}, Jan and Sanjay Popat and Vogelzang, {Nicholas J} and Federica Grosso and Rasha Aboelhassan and Marko Jakopovic and Ceresoli, {Giovanni L} and Paul Taylor and Francisco Orlandi and Fennell, {Dean A} and Silvia Novello and Arnaud Scherpereel and Kozo Kuribayashi and Susana Cedres and S{\o}rensen, {Jens Benn} and Nick Pavlakis and Martin Reck and Derek Velema and {von Wangenheim}, Ute and Miyoung Kim and Jos{\'e} Barrueco and Tsao, {Anne S}",
note = "Copyright {\circledC} 2019 Elsevier Ltd. All rights reserved.",
year = "2019",
month = "7",
doi = "10.1016/S2213-2600(19)30139-0",
language = "English",
volume = "7",
pages = "569--580",
journal = "The Lancet Respiratory Medicine",
issn = "2213-2600",
publisher = "Elsevier",
number = "7",

}

RIS

TY - JOUR

T1 - Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso)

T2 - a double-blind, randomised, placebo-controlled phase 3 trial

AU - Scagliotti, Giorgio V

AU - Gaafar, Rabab

AU - Nowak, Anna K

AU - Nakano, Takashi

AU - van Meerbeeck, Jan

AU - Popat, Sanjay

AU - Vogelzang, Nicholas J

AU - Grosso, Federica

AU - Aboelhassan, Rasha

AU - Jakopovic, Marko

AU - Ceresoli, Giovanni L

AU - Taylor, Paul

AU - Orlandi, Francisco

AU - Fennell, Dean A

AU - Novello, Silvia

AU - Scherpereel, Arnaud

AU - Kuribayashi, Kozo

AU - Cedres, Susana

AU - Sørensen, Jens Benn

AU - Pavlakis, Nick

AU - Reck, Martin

AU - Velema, Derek

AU - von Wangenheim, Ute

AU - Kim, Miyoung

AU - Barrueco, José

AU - Tsao, Anne S

N1 - Copyright © 2019 Elsevier Ltd. All rights reserved.

PY - 2019/7

Y1 - 2019/7

N2 - BACKGROUND: Nintedanib targets VEGF receptors 1-3, PDGF receptors α and β, FGF receptors 1-3, and Src and Abl kinases, which are all implicated in malignant pleural mesothelioma pathogenesis. Here, we report the final results of the phase 3 part of the LUME-Meso trial, which aimed to investigate the efficacy and safety of pemetrexed plus cisplatin combined with nintedanib or placebo in unresectable malignant pleural mesothelioma.METHODS: This double-blind, randomised, placebo-controlled phase 3 trial was done at 120 academic medical centres and community clinics in 27 countries across the world. Chemotherapy-naive adults (aged ≥18 years) with unresectable epithelioid malignant pleural mesothelioma and ECOG performance status 0-1 were randomly assigned 1:1 via an independently verified random number-generating system to receive up to six 21-day cycles of pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on day 1, then nintedanib (200 mg twice daily) or matched placebo on days 2-21. Patients without disease progression after six cycles received nintedanib or placebo maintenance on days 1-21 of each cycle. The primary endpoint was progression-free survival (investigator-assessed according to mRECIST) in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of their assigned study drug. This study is registered with ClinicalTrials.gov, number NCT01907100.FINDINGS: Between April 14, 2016, and Jan 5, 2018, 541 patients were screened and 458 were randomly assigned to either the nintedanib group (n=229) or the placebo group (n=229). Median treatment duration was 5·3 months (IQR 2·8-7·3) in the nintedanib group and 5·1 months (2·7-7·8) in the placebo group. After 250 events, progression-free survival was not different between the nintedanib group (median 6·8 months [95% CI 6·1-7·0]) and the placebo group (7·0 months [6·7-7·2]; HR 1·01 [95% CI 0·79-1·30], p=0·91). The most frequently reported grade 3 or worse adverse event in both treatment groups was neutropenia (73 [32%] in the nintedanib group vs 54 [24%] in the placebo group). Serious adverse events were reported in 99 (44%) patients in the nintedanib group and 89 (39%) patients in the placebo group. The only serious adverse event occurring in at least 5% of patients in either group was pulmonary embolism (13 [6%] vs seven [3%]).INTERPRETATION: The primary progression-free survival endpoint of the phase 3 part of LUME-Meso was not met and phase 2 findings were not confirmed. No unexpected safety findings were reported.FUNDING: Boehringer Ingelheim.

AB - BACKGROUND: Nintedanib targets VEGF receptors 1-3, PDGF receptors α and β, FGF receptors 1-3, and Src and Abl kinases, which are all implicated in malignant pleural mesothelioma pathogenesis. Here, we report the final results of the phase 3 part of the LUME-Meso trial, which aimed to investigate the efficacy and safety of pemetrexed plus cisplatin combined with nintedanib or placebo in unresectable malignant pleural mesothelioma.METHODS: This double-blind, randomised, placebo-controlled phase 3 trial was done at 120 academic medical centres and community clinics in 27 countries across the world. Chemotherapy-naive adults (aged ≥18 years) with unresectable epithelioid malignant pleural mesothelioma and ECOG performance status 0-1 were randomly assigned 1:1 via an independently verified random number-generating system to receive up to six 21-day cycles of pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on day 1, then nintedanib (200 mg twice daily) or matched placebo on days 2-21. Patients without disease progression after six cycles received nintedanib or placebo maintenance on days 1-21 of each cycle. The primary endpoint was progression-free survival (investigator-assessed according to mRECIST) in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of their assigned study drug. This study is registered with ClinicalTrials.gov, number NCT01907100.FINDINGS: Between April 14, 2016, and Jan 5, 2018, 541 patients were screened and 458 were randomly assigned to either the nintedanib group (n=229) or the placebo group (n=229). Median treatment duration was 5·3 months (IQR 2·8-7·3) in the nintedanib group and 5·1 months (2·7-7·8) in the placebo group. After 250 events, progression-free survival was not different between the nintedanib group (median 6·8 months [95% CI 6·1-7·0]) and the placebo group (7·0 months [6·7-7·2]; HR 1·01 [95% CI 0·79-1·30], p=0·91). The most frequently reported grade 3 or worse adverse event in both treatment groups was neutropenia (73 [32%] in the nintedanib group vs 54 [24%] in the placebo group). Serious adverse events were reported in 99 (44%) patients in the nintedanib group and 89 (39%) patients in the placebo group. The only serious adverse event occurring in at least 5% of patients in either group was pulmonary embolism (13 [6%] vs seven [3%]).INTERPRETATION: The primary progression-free survival endpoint of the phase 3 part of LUME-Meso was not met and phase 2 findings were not confirmed. No unexpected safety findings were reported.FUNDING: Boehringer Ingelheim.

U2 - 10.1016/S2213-2600(19)30139-0

DO - 10.1016/S2213-2600(19)30139-0

M3 - Journal article

VL - 7

SP - 569

EP - 580

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

SN - 2213-2600

IS - 7

ER -

ID: 57751762